🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06542042
Starting soon Observational

Application of Nanopore Adaptive Sequencing

NCT06542042 · tracked via the Priya Life Science China tracker
Sponsor
Shenzhen Third People's Hospital
Phase
Observational
Started
2024-10-01
Last updated
2024-08-07

Condition(s) studied

Liver Transplant Infection

Investigational drug(s) / intervention(s)

NAS, NGS and Laboratory tests

NAS, NGS and Laboratory tests: Using three diffrent detection methods and comparing their efficiency

Study summary

Infection post liver transplantation is an important factor in the death in patients. The traditional method of diagnosing infection post liver transplantation is laboratory tests. But the sensitivity and specificity of blood tests is poor. Next-generation sequencing (NGS) has greater detection rate for mycobacterium tuberculosis, anaerobes and fungi and greater sensitivity compare with blood tests. However use of NGS is limited because of the short read-length. Oxford nanopore adaptive sequencing (NAS) method is the Third Revolution in Sequencing Technology. For each 1 Gbp of data, NAS sequencing detected 45 times more microbiome sequences than Nanopore standard sequencing and 2.5 times more than Illumina sequencing. The purpose of this study is to compare NAS with NGS and laboratory tests for the diagnostic rate of infection post liver transplantation.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria: * Accept liver transplantation * Signing informed consent voluntarily * Possessing ability to comprehend material information * Participating this study voluntarily Exclusion Criteria: * Participated another study * Graft loss * Have undergone a multi-organ transplantion or have had a previous organ transplantation * Patient died

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shenzhen Third People's Hospital Shenzhen Guangdong

More Shenzhen Third People's Hospital trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06542042 on ClinicalTrials.gov ↗ ← All trials in China